With the identification of biomarkers for tumor or patient selection for future clinical trials targeting TGF-β as the major goal of this study, it is important to note that we had no opportunity to explore whether host cells, notably immune cells, were susceptible to tumor-derived TGF-β. The gene discussed is TGFB1; the disease is neoplasm.